Alai Goñi Ramirez Shares 11-Year Study on HDR Brachytherapy for High-Risk Prostate Cancer
Alai Goñi Ramirez/LinkedIn

Alai Goñi Ramirez Shares 11-Year Study on HDR Brachytherapy for High-Risk Prostate Cancer

Alai Goñi Ramirez Radiation Oncologist at Onkologikoa, shared on LinkedIn:

“I’m excited to share that our latest work has just been published in Practical Radiation Oncology: American Society for Radiation Oncology (ASTRO)

We compared single-fraction (15 Gy) and two-fraction (9-10 Gy) HDR brachytherapy boosts combined with EBRT in 378 patients with high-risk prostate cancer. Median follow-up was nearly 11 years.

Key findings:

  • There was no significant difference in 10-year oncologic control (bRFS 79.6% vs. 82.6%; CSS 95.3% vs. 95.4%).
  • Grade ≥3 GU toxicity was lower with a single fraction (10.4% vs. 22.9%).

A single 15 Gy fraction appears to be an adequate boost combined with EBRT. Because this was a non-randomized comparison, prospective studies are needed to confirm it.

Many thanks to the team at Donostia Ospitalea / Hospital Donostia and Naru Healthcare, and above all to our patients.”

Read the Full Article

Title: Single- Versus Two-Fraction HDR Brachytherapy Boost for Prostate Cancer: Long-Term Oncologic and Toxicity Outcomes

Authors: Alai Goñi, Macarena Sevilla, Mikel Larruskain, Mikel Eguiguren, Ainhoa Perez, Eva Sáenz de Urturi, Usoa Iceta, Daniel Alberto Roura, Maider Alberich, Julian Minguez, Jose María Urraca, Arrate Querejeta.

You may also be interested in:

Alai Goñi Ramirez Shares 11-Year Study on HDR Brachytherapy for High-Risk Prostate Cancer